+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
TNF Inhibitors for the Treatment of Plaque Psoriasis Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
TNF Inhibitors for the Treatment of Plaque Psoriasis Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

TNF Inhibitors for the Treatment of Plaque Psoriasis Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6082419
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Plaque psoriasis remains a chronic, immune‐mediated dermatological condition affecting millions worldwide, characterized by erythematous, scaly lesions that impair both physical comfort and quality of life. Tumor necrosis factor (TNF) inhibitors have revolutionized management by targeting a pivotal proinflammatory cytokine, offering rapid symptom relief and sustained disease control. Inhibitors such as adalimumab, etanercept, and infliximab have demonstrated robust efficacy across diverse patient populations, setting a high bar for safety and long‐term tolerability.

As biologic patents expire, the entry of biosimilars is reshaping competitive dynamics, driving down costs and expanding patient access. Meanwhile, evolving regulatory frameworks, technological advancements, and heightened patient expectations are prompting manufacturers to adopt more agile development strategies. By examining the current landscape, this summary highlights transformative shifts, tariff impacts, segmentation nuances, regional trends, key corporate maneuvers, and strategic recommendations that will guide stakeholders through an increasingly complex market.

Transformative Shifts Reshaping the TNF Inhibitor Landscape

The plaque psoriasis arena has undergone seismic shifts over the past decade. First, the proliferation of biosimilars for adalimumab, etanercept, and infliximab has increased pricing pressure on established brands, while forcing originators to innovate in patient support and real‐world evidence generation. Concurrently, the integration of digital health tools-ranging from teledermatology platforms to adherence‐tracking apps-has elevated patient engagement and streamlined care pathways.

Moreover, regulators worldwide are adopting more harmonized approval processes, creating pathways for expedited access to next‐generation biologics and biosimilars. Real‐world data initiatives now play a central role in post‐launch safety monitoring and value demonstration, prompting manufacturers to forge partnerships with payers and health systems. Finally, patient advocacy groups wield greater influence in shaping formulary decisions, demanding transparent pricing and robust risk‐sharing agreements. Collectively, these developments are redefining competitive moats, support models, and value propositions across the TNF inhibitor landscape.

Cumulative Impact of 2025 United States Tariffs on Biologic Therapeutics

The introduction of revised United States tariffs in 2025 has reverberated across the supply chain for TNF inhibitors. By imposing higher duties on imported active pharmaceutical ingredients and finished biologics, these measures have elevated manufacturing and distribution costs for both originator companies and biosimilar producers. Consequently, many manufacturers have reevaluated offshore production strategies, considering near‐shoring raw material synthesis to mitigate customs expenses and potential delays.

Meanwhile, wholesalers and specialty pharmacies are renegotiating service agreements to accommodate the new duty structures, with some absorbing marginal cost increases to preserve price competitiveness. Nevertheless, higher landed costs have compounded pricing pressures in a market already driven by value‐based procurement approaches. Decision‐makers must now balance the imperative to maintain attractive list prices against the need to protect gross margins. Ultimately, these tariff changes underscore the importance of supply‐chain resilience, cost‐efficiency measures, and dynamic pricing strategies in sustaining market momentum for TNF inhibitors.

Key Segmentation Insights Illuminating Market Dynamics

A granular view of market segments reveals where opportunities and challenges intersect across the TNF inhibitor portfolio. When dissecting by drug type, biosimilars of adalimumab, etanercept, and infliximab have captured significant share as payers leverage lower‐cost alternatives, although established brands of those same molecules continue to command loyalty through well‐entrenched rebate and patient assistance programs. In terms of formulation, subcutaneous injections dominate outpatient settings due to greater convenience, whereas intravenous infusions retain a strong presence in hospital‐based infusions, particularly for patients requiring intensive monitoring or combination regimens.

Patient demographics present nuanced adoption patterns: middle‐aged and older adults often rely on tried‐and‐true therapies with proven long‐term safety, while young adults increasingly seek convenient self‐administered options. Pediatric patients, stratified into adolescent, child, and infant cohorts, require tailored dosing and safety protocols, driving demand for formulations specifically approved for younger age groups. Treatment type analysis reveals first‐line monotherapy remains the entry point for most newly diagnosed cases, yet combination therapy is rising among patients with moderate to severe disease to optimize efficacy and mitigate immunogenicity. Second‐line therapy captures those who experience primary or secondary loss of response, underscoring the importance of pipeline diversification.

Severity‐based segmentation shows mild plaque psoriasis still receives topical or phototherapy adjuncts, but moderate and severe cases rely heavily on systemic TNF inhibitors. Distribution channels span hospital pharmacies for inpatient or infusion care, specialty clinics for managed administration, retail and online pharmacies for subcutaneous self‐injection, and growing homecare settings that enable at‐home infusions. Within application categories, chronic plaque psoriasis represents the largest use case, while erythrodermic, guttate, inverse, and pustular forms demand more aggressive management, often involving combination or second‐line regimens. Finally, origin delineation between biological and synthetic platforms highlights ongoing innovation in fusion proteins and antibody engineering, balanced against traditional synthetic small molecules that may serve adjunctive roles.

Regional Variations Driving TNF Inhibitor Adoption and Access

Geographic markets exhibit distinct regulatory, economic, and cultural drivers that shape TNF inhibitor uptake. In the Americas, robust reimbursement frameworks and mature biosimilar guidelines accelerate access to both originator and biosimilar therapies. Canada and the United States lead in real‐world evidence generation and value‐based contracts, whereas Latin American markets emphasize cost containment, favoring lower‐priced biosimilars when supply chains remain stable.

In Europe, Middle East & Africa (EMEA), established centralized approval processes and purchasing consortia foster broad formulary inclusion, but heterogeneous national health systems result in variable uptake rates. Western European nations lean on extensive post‐marketing safety registries, while emerging markets in the Middle East and Africa face logistical hurdles and tariff complexities that can impede distribution.

Asia‐Pacific dynamics vary significantly: Japan and Australia maintain stringent local clinical data requirements, supporting strong originator pipelines, whereas markets such as China and India prioritize domestic manufacturing and local partnerships to reduce costs and meet surging patient demand. Telemedicine adoption in Asia‐Pacific is rapidly gaining traction, offering a platform to expand access to rural and underserved populations. Across all regions, cultural attitudes toward biologics, reimbursement policy shifts, and supply‐chain disruptions continue to influence strategic decisions and market share trajectories.

Competitive Landscape: Leading Companies and Strategic Initiatives

Leading pharmaceutical and biotech firms are pursuing differentiated approaches to capture value in the evolving TNF inhibitor segment. AbbVie Inc. remains a global leader with adalimumab, reinforcing its position through robust patient support and digital health integration. Amgen Inc. has bolstered its etanercept biosimilar franchise, leveraging manufacturing scale to offer competitive pricing. AstraZeneca PLC and Boehringer Ingelheim International GmbH focus on pipeline diversification, evaluating next‐generation fusion proteins to extend patent lifespans and address immunogenicity concerns.

Bristol-Myers Squibb Company and its subsidiary Celgene Corporation capitalize on cross‐portfolio synergies, combining TNF inhibitors with emerging small‐molecule immunomodulators. Eisai Co., Ltd. and Eli Lilly and Company invest in biomarker research to refine patient selection and optimize real‐world outcomes. Johnson & Johnson Services, Inc. reinforces supply‐chain resilience by establishing regional manufacturing hubs, while Novartis AG exploits digital recruitment and telehealth partnerships to accelerate clinical trials in underserved regions.

Pfizer Inc. pursues value‐based agreements with payers, aligning rebates with real‐world clinical endpoints, and Sun Pharmaceutical Industries Ltd. expands its biosimilar offerings in cost‐sensitive markets. UCB S.A. underscores its commitment to rare and severe psoriasis subtypes through targeted therapy programs and specialized training for healthcare providers. Collectively, these players underscore the importance of innovation, pricing agility, and strategic alliances in sustaining growth and addressing unmet needs across global markets.

Actionable Recommendations for Industry Leaders

To thrive in an increasingly competitive environment, industry leaders must adopt a multipronged strategy. First, accelerating biosimilar development and approval through streamlined trials and adaptive regulatory pathways will capture early‐entrance advantages. Second, investing in digital health platforms-from teledermatology to AI‐driven adherence tools-can differentiate patient engagement models and reinforce brand loyalty. Third, forging risk‐sharing and value‐based contracting agreements with payers will align reimbursement with clinical outcomes and support sustainable pricing structures.

Fourth, diversifying supply chains by near‐shoring critical manufacturing processes will mitigate tariff impacts and logistical disruptions. Fifth, tailoring patient support programs for specific demographic segments-young adults seeking self‐administration, pediatric caregivers requiring safety assurances, and older adults desiring comprehensive monitoring-will enhance uptake and adherence. Sixth, deepening partnerships with academic centers and patient advocacy groups can strengthen real‐world evidence generation and shape guidelines for severe and atypical psoriasis forms. Finally, embedding environmental, social, and governance (ESG) principles into corporate strategy-such as reducing biologic waste from infusion centers-will meet rising stakeholder expectations and future‐proof market access.

Conclusion: Navigating Future Growth and Innovation

The TNF inhibitor market stands at a critical juncture, balancing the promise of biosimilars and next‐generation biologics against cost pressures and evolving regulatory landscapes. Stakeholders must remain vigilant to tariff developments, shifting reimbursement models, and emerging competitive threats. Collaborative efforts that integrate digital innovation, real‐world evidence, and patient‐centric support will be key to sustaining differentiation in a mature market.

Moreover, regional dynamics-from the Americas’ value‐based contracts to Asia‐Pacific’s domestic manufacturing priorities-require tailored go‐to‐market strategies. Companies that proactively engage with payers, regulators, and advocacy groups will not only expedite access but also strengthen their positioning as trusted partners in long‐term disease management. Ultimately, the ability to adapt rapidly, invest in targeted innovation, and optimize cost structures will determine leadership in the dynamic plaque psoriasis segment.

Market Segmentation & Coverage

This research report categorizes the TNF Inhibitors for the Treatment of Plaque Psoriasis Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biosimilars of Adalimumab
  • Biosimilars of Etanercept
  • Biosimilars of Infliximab
  • Established Brands
    • Adalimumab
    • Etanercept
    • Infliximab
  • Intravenous Infusion
  • Subcutaneous Injection
  • Adult
    • Middle Age (36-55 Years)
    • Older Adult (56+ Years)
    • Young Adult (18-35 Years)
  • Pediatric
    • Adolescent (13-17 Years)
    • Child (3-12 Years)
    • Infant (0-2 Years)
  • Combination Therapy
  • First-Line Therapy
  • Second-Line Therapy
  • Mild Plaque Psoriasis
  • Moderate Plaque Psoriasis
  • Severe Plaque Psoriasis
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Specialty Clinics
  • Chronic Plaque Psoriasis
  • Erythrodermic Psoriasis
  • Guttate Psoriasis
  • Inverse Psoriasis
  • Pustular Psoriasis
  • Ambulatory Surgical Centers
  • Homecare Settings
  • Hospitals
  • Specialty Clinics
  • Biological
  • Synthetic

This research report categorizes the TNF Inhibitors for the Treatment of Plaque Psoriasis Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the TNF Inhibitors for the Treatment of Plaque Psoriasis Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation (a Bristol-Myers Squibb Company)
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • UCB S.A.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. TNF Inhibitors for the Treatment of Plaque Psoriasis Market, by Drug Type
8.1. Introduction
8.2. Biosimilars of Adalimumab
8.3. Biosimilars of Etanercept
8.4. Biosimilars of Infliximab
8.5. Established Brands
8.5.1. Adalimumab
8.5.2. Etanercept
8.5.3. Infliximab
9. TNF Inhibitors for the Treatment of Plaque Psoriasis Market, by Formulation
9.1. Introduction
9.2. Intravenous Infusion
9.3. Subcutaneous Injection
10. TNF Inhibitors for the Treatment of Plaque Psoriasis Market, by Patient Demographics
10.1. Introduction
10.2. Adult
10.2.1. Middle Age (36-55 Years)
10.2.2. Older Adult (56+ Years)
10.2.3. Young Adult (18-35 Years)
10.3. Pediatric
10.3.1. Adolescent (13-17 Years)
10.3.2. Child (3-12 Years)
10.3.3. Infant (0-2 Years)
11. TNF Inhibitors for the Treatment of Plaque Psoriasis Market, by Treatment Type
11.1. Introduction
11.2. Combination Therapy
11.3. First-Line Therapy
11.4. Second-Line Therapy
12. TNF Inhibitors for the Treatment of Plaque Psoriasis Market, by Severity of Condition
12.1. Introduction
12.2. Mild Plaque Psoriasis
12.3. Moderate Plaque Psoriasis
12.4. Severe Plaque Psoriasis
13. TNF Inhibitors for the Treatment of Plaque Psoriasis Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
13.5. Specialty Clinics
14. TNF Inhibitors for the Treatment of Plaque Psoriasis Market, by Application
14.1. Introduction
14.2. Chronic Plaque Psoriasis
14.3. Erythrodermic Psoriasis
14.4. Guttate Psoriasis
14.5. Inverse Psoriasis
14.6. Pustular Psoriasis
15. TNF Inhibitors for the Treatment of Plaque Psoriasis Market, by End User
15.1. Introduction
15.2. Ambulatory Surgical Centers
15.3. Homecare Settings
15.4. Hospitals
15.5. Specialty Clinics
16. TNF Inhibitors for the Treatment of Plaque Psoriasis Market, by Origin
16.1. Introduction
16.2. Biological
16.3. Synthetic
17. Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. AbbVie Inc.
20.3.2. Amgen Inc.
20.3.3. AstraZeneca PLC
20.3.4. Boehringer Ingelheim International GmbH
20.3.5. Bristol-Myers Squibb Company
20.3.6. Celgene Corporation (a Bristol-Myers Squibb Company)
20.3.7. Eisai Co., Ltd.
20.3.8. Eli Lilly and Company
20.3.9. Johnson & Johnson Services, Inc.
20.3.10. Novartis AG
20.3.11. Pfizer Inc.
20.3.12. Sun Pharmaceutical Industries Ltd.
20.3.13. UCB S.A.
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET MULTI-CURRENCY
FIGURE 2. TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET MULTI-LANGUAGE
FIGURE 3. TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 22. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2024 VS 2030 (%)
FIGURE 24. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY BIOSIMILARS OF ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY BIOSIMILARS OF ETANERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY BIOSIMILARS OF INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY MIDDLE AGE (36-55 YEARS), BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY OLDER ADULT (56+ YEARS), BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY YOUNG ADULT (18-35 YEARS), BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADOLESCENT (13-17 YEARS), BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY CHILD (3-12 YEARS), BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY INFANT (0-2 YEARS), BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FIRST-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY MILD PLAQUE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY MODERATE PLAQUE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERE PLAQUE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY CHRONIC PLAQUE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY BIOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 93. CANADA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 94. CANADA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 95. CANADA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 96. CANADA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 97. CANADA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 98. CANADA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 99. CANADA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. CANADA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 101. CANADA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. CANADA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. CANADA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. CANADA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 105. MEXICO TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. MEXICO TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 108. MEXICO TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 110. MEXICO TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 111. MEXICO TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. MEXICO TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 113. MEXICO TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. MEXICO TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. MEXICO TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. MEXICO TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 155. CHINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 156. CHINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 157. CHINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 158. CHINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 159. CHINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 160. CHINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 161. CHINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 162. CHINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 163. CHINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. CHINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. CHINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. CHINA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 167. INDIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. INDIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 169. INDIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 170. INDIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 171. INDIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 172. INDIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 173. INDIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 174. INDIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 175. INDIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. INDIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. INDIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. INDIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. INDONESIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. INDONESIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. INDONESIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 191. JAPAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 192. JAPAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 193. JAPAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 194. JAPAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 195. JAPAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 196. JAPAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 197. JAPAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. JAPAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 199. JAPAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. JAPAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. JAPAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. JAPAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 208. MALAYSIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 209. MALAYSIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 210. MALAYSIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 211. MALAYSIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. MALAYSIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 220. PHILIPPINES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 221. PHILIPPINES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 222. PHILIPPINES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 223. PHILIPPINES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. PHILIPPINES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. PHILIPPINES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. PHILIPPINES TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 227. SINGAPORE TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 232. SINGAPORE TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 233. SINGAPORE TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. SINGAPORE TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 235. SINGAPORE TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. SINGAPORE TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. SINGAPORE TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. SINGAPORE TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. SOUTH KOREA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 247. SOUTH KOREA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. SOUTH KOREA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. SOUTH KOREA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. SOUTH KOREA TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 251. TAIWAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY ESTABLISHED BRANDS, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 254. TAIWAN TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation (a Bristol-Myers Squibb Company)
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • UCB S.A.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Chronic Plaque Psoriasis Market Report 2025 - Product Image

Chronic Plaque Psoriasis Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Psoriasis Treatment Market Report and Forecast 2024-2032 - Product Image

Psoriasis Treatment Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Psoriasis Drugs Market by Therapeutic Class, Type of Treatment, Mechanism of Action, Route of Administration, Distribution Channel, Application - Global Forecast 2025-2030 - Product Image

Psoriasis Drugs Market by Therapeutic Class, Type of Treatment, Mechanism of Action, Route of Administration, Distribution Channel, Application - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Psoriasis - Pipeline Insight, 2025 - Product Image

Psoriasis - Pipeline Insight, 2025

  • Clinical Trials
  • 100 Pages
  • Global
From
Psoriasis Market Report 2025 - Product Image

Psoriasis Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.